

Presymptomatic Staging of Type 1 Diabetes for Pediatric Nurse Practitioners

Alexandra Armstrong, CRNP, CPNP-AC abarmstrong@uab.edu

Leslie Pitts, CRNP, CPNP-AC, CDCES, AP-PEN lesliepitts@uab.edu

Resources

Resources for Providers

- [Healthcare Provider Education](#)
- [Screening Guide](#)
- [Enable Biosciences Antibody Screening](#)
- [LabCorp Diabetes Autoantibody Profile](#)
- [Quest Diagnostics Autoantibodies and Type 1 Diabetes](#)
- [Mayo Lab Type 1 Diabetes Antibody Panel](#)
- [Teplizumab \(Tzield\) for Healthcare Professionals Website](#)
- [Patient Criteria for Teplizumab \(Tzield\) Therapy](#)
- [Teplizumab \(Tzield\) Prescribing Information](#)
- [Patient Support through the Prevention Bio Compass Program](#)

Resources for Patients

- [T1D Screening through Trialnet](#)
- [Screening Options](#)
- [JDRF T1 Detect](#)
- [Teplizumab \(Tzield\) Discussion Guide](#)
- [Teplizumab \(Tzield\) Website](#)
- [Prevention Bio Compass Patient Support Program](#)

References

- Chua, K.-P., Lee, J. M., & Conti, R. M. (2020). Out-of-pocket spending for insulin, diabetes-related supplies, and other health care services among privately insured US patients with type 1 diabetes. *JAMA Internal Medicine*, 180(7), 1012.
<https://doi.org/10.1001/jamainternmed.2020.1308>
- Fisher, L., Hessler, D., Polonsky, W., Strycker, L., Masharani, U., & Peters, A. (2016). Diabetes distress in adults with type 1 diabetes: Prevalence, incidence and change over time. *Journal of Diabetes and Its Complications*, 30(6), 1123-1128.
<https://doi.org/10.1016/j.jdiacomp.2016.03.03>
- Foster, N. C., Beck, R. W., Miller, K. M., Clements, M. A., Rickels, M. R., Dimeglio, L. A., Maahs, D. M., Tamborlane, W. V., Bergenstal, R., Smith, E., Olson, B. A., & Garg, S. K. (2019). State of type 1 diabetes management and outcomes from the T1D Exchange in 2016–2018. *Diabetes Technology & Therapeutics*, 21(2), 66-72.
<https://doi.org/10.1089/dia.2018.0384>
- Herold, K. C., Bundy, B. N., Long, S. A., Bluestone, J. A., DiMeglio, L. A., Dufort, M. J., Gitelman, S. E., Gottlieb, P. A., Krischer, J. P., Linsley, P. S., Marks, J. B., Moore, W., Moran, A., Rodriguez, H., Russell, W. E., Schatz, D., Skyler, J. S., Tsalikian, E., Wherrett, D. K., Ziegler, A. G., ... Type 1 Diabetes TrialNet Study Group (2019). An anti-CD3 antibody, Teplizumab, in relatives at risk for type 1 diabetes. *The New England Journal of Medicine*, 381(7), 603–613.
<https://doi-org.uab.idm.oclc.org/10.1056/NEJMoa1902226>
- Maffi, P., & Secchi, A. (2017). The burden of diabetes: Emerging data. *Developments in Ophthalmology*, 60, 1-5. <https://doi.org/10.1159/000459641>

Miller, K. M., Foster, N. C., Beck, R. W., Bergenstal, R. M., Dubose, S. N., Dimeglio, L. A.,

Maahs, D. M., & Tamborlane, W. V. (2015). Current state of type 1 diabetes treatment in the U.S.: Updated data from the T1D Exchange clinic registry. *Diabetes Care*, 38(6), 971-978. <https://doi.org/10.2337/dc15-0078>

Nourelden, A. Z., Elshanbary, A. A., El-Sherif, L., Benmelouka, A. Y., Rohim, H. I., Helmy, S. K.,

Sayed, M. K., Ismail, A., Ali, A. S., Ragab, K. M., & Zaazouee, M. S. (2021). Safety and efficacy of Teplizumab for treatment of type one diabetes mellitus: A systematic review and meta-analysis. *Endocrine, Metabolic & Immune Disorders Drug Targets*, 21(10), 1895–1904. <https://doi-org.uab.idm.oclc.org/10.2174/1871530320999201209222921>

Provention Bio, Inc (2023). Retrieved January 28, 2024, from

<https://products.sanofi.us/tzield/tzield.pdf>

Sims, E. K., Bundy, B. N., Stier, K., Serti, E., Lim, N., Long, S. A., Geyer, S. M., Moran, A.,

Greenbaum, C. J., Evans-Molina, C., Herold, K. C., & Type 1 Diabetes TrialNet Study Group (2021). Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals. *Science Translational Medicine*, 13(583), eabc8980.

<https://doi-org.uab.idm.oclc.org/10.1126/scitranslmed.abc8980>

Sussman, M., Benner, J., Haller, M. J., Rewers, M., & Griffiths, R. (2020). Estimated lifetime

economic burden of type 1 diabetes. *Diabetes Technology & Therapeutics*, 22(2), 121-130. <https://doi.org/10.1089/dia.2019.0398>

Wagenknecht, L. E., Lawrence, J. M., Isom, S., Jensen, E. T., Dabelea, D., Liese, A. D., Dolan,

L. M., Shah, A. S., Bellatorre, A., Sauder, K., Marcovina, S., Reynolds, K., Pihoker, C.,

Imperatore, G., & Divers, J. (2023). Trends in incidence of youth-onset type 1 and type 2

diabetes in the USA, 2002-18: Results from the population-based SEARCH for diabetes in youth study. *Lancet Diabetes Endocrinology*, 11(4), 242-250.

[https://doi.org/10.1016/s2213-8587\(23\)00025-6](https://doi.org/10.1016/s2213-8587(23)00025-6)